Adams JD Jr., Wang B, Klaidman LK, LeBel CP, Odunze IN, et al
NICE guidance (NG100) recommends disease-modifying antirheumatic drugs (DMARDs) as standard care, with methotrexate as first-line therapy
Some people start with semaglutide, some later switch to tirzepatide, and some stop and restart after talking with a clinician about side effects, cost, or goals
According to the American Society for Metabolic and Bariatric Surgery, surgical patients lose up to five times more weight at two years compared to those using semaglutide or tirzepatide, with sustained benefits for a decade or more, whereas most medication users regain weight once treatment stops
GLP-1-RA mimic the actions of GLP-1, binding the GLP-1 receptor on the surface of cells (and other cell types) and stimulating insulin secretion in the presence of elevated glucose